How Much Does Vyleesi Cost in Minnesota in 2026?

Brand-Name Vyleesi Pricing at Minnesota Pharmacies

The manufacturer list price set by Palatin Technologies for Vyleesi (bremelanotide 1.75 mg/0.3 mL prefilled autoinjector) is $1,200 per month. Minnesota retail pharmacies, including chains like CVS, Walgreens, and Hy-Vee, price the medication at or near this figure for cash-pay patients. This places it among the most expensive on-demand sexual health medications currently available in the state.

Each carton contains a set number of single-use autoinjectors. Because bremelanotide is dosed as needed rather than daily, actual monthly cost depends on frequency of use. A patient using 4 doses per month still pays the full carton price at most retail counters. The FDA label specifies a maximum of 8 doses in any 30-day period 1.

Price variation across Minnesota metro versus rural pharmacies is minimal. Independent pharmacies in Duluth, Rochester, and St. Cloud report near-identical pricing to Twin Cities locations because the drug has a single wholesale acquisition cost with limited discount competition.

Minnesota Medicaid Coverage and Prior Authorization

Minnesota Medical Assistance (Medicaid) covers Vyleesi with prior authorization (PA). The PA process requires documentation of a clinical diagnosis of HSDD in a premenopausal woman, along with evidence that non-pharmacologic interventions or alternative therapies were considered or attempted.

Prescribers must submit the PA request through the state's pharmacy benefit manager. Typical approval turnaround is 5 to 10 business days. The documentation package should include chart notes confirming the diagnosis meets DSM-5 criteria for female sexual interest/arousal disorder with predominantly desire-related distress 2.

Minnesota's coverage with PA places it in a more favorable tier than several neighboring states. Wisconsin, for instance, does not list Vyleesi on its preferred drug list at all. For Medicaid enrollees in Minnesota who receive approval, copays are typically $0 to $3 per prescription fill.

Denials can be appealed. The most common denial reason is insufficient documentation of HSDD severity or missing trial of cognitive-behavioral therapy. Clinicians should note scores from validated instruments like the Female Sexual Function Index (FSFI) or the Female Sexual Distress Scale-Revised (FSDS-R) in the PA submission.

Compounded Bremelanotide in Minnesota: Legality and Cost

Compounded bremelanotide is legal in Minnesota when dispensed by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits pharmacies to compound medications that are not essentially copies of commercially available drugs, provided they meet specific criteria. Because compounded bremelanotide uses different concentrations, vial formats, or delivery methods than the branded autoinjector, 503A pharmacies in Minnesota can legally prepare it.

The average cost for compounded bremelanotide from Minnesota 503A pharmacies is $140 per month. This represents an 88% savings compared to brand-name Vyleesi. Compounded formulations are typically dispensed as multi-dose vials with insulin syringes for subcutaneous self-injection rather than as prefilled autoinjectors.

Patients considering the compounded route should verify that their pharmacy holds a valid Minnesota Board of Pharmacy compounding license and operates under 503A (not 503B outsourcing facility) rules. The prescriber writes for bremelanotide by its generic name with specific concentration and volume instructions.

Dr. Sheryl Kingsberg, a researcher on the RECONNECT trials, has noted: "Bremelanotide works through a distinct mechanism, activating melanocortin receptors in the central nervous system rather than targeting peripheral blood flow. The pharmacologic effect is the same regardless of the delivery device" 2.

Insurance Coverage Beyond Medicaid

Commercial insurance coverage for Vyleesi in Minnesota varies by plan and tier placement. Most major carriers operating in the state, including Blue Cross Blue Shield of Minnesota, HealthPartners, Medica, and UnitedHealthcare, have Vyleesi on their formularies but place it on specialty or non-preferred brand tiers with step therapy or PA requirements.

Typical out-of-pocket costs with commercial insurance after PA approval:

Preferred brand tier plans charge $50 to $75 per fill. Specialty tier plans charge $150 to $300 per fill depending on coinsurance percentage. High-deductible health plans require full cost until the deductible is met, then 20% to 40% coinsurance applies.

Step therapy requirements commonly mandate a trial of flibanserin (Addyi) before approving bremelanotide. This means patients may need to document a 60-day trial of oral flibanserin, or document a clinical reason why flibanserin is contraindicated (alcohol use disorder history, hepatic impairment, concomitant CYP3A4 inhibitor use), before the insurer authorizes Vyleesi.

Minnesota state law does not mandate coverage of HSDD treatments specifically, so coverage remains at the discretion of individual plan benefit designs. Patients on MNsure marketplace plans should check their specific formulary before assuming access.

The Palatin Technologies Savings Card

Palatin Technologies offers a manufacturer copay assistance card that reduces out-of-pocket costs for commercially insured patients. The card covers up to a specified dollar amount per prescription fill, bringing the patient's copay as low as $0 in some cases.

Eligibility requirements include active commercial insurance coverage (government plans like Medicaid, Medicare, and Tricare are excluded), a valid prescription for Vyleesi, and residency in a state where the program operates. Minnesota residents with commercial insurance qualify.

The savings card does not apply to the full cash price for uninsured patients. It functions as a copay offset only when insurance processes the claim first. Uninsured patients seeking brand-name Vyleesi have no manufacturer patient assistance program that reduces the $1,200 list price, which makes the compounded route significantly more relevant for this population.

To activate the card, patients register through the manufacturer's website or receive enrollment materials from their prescriber's office. The card is presented at the pharmacy alongside the insurance card at time of fill.

Telehealth Prescribing of Vyleesi in Minnesota

Minnesota permits telehealth prescribing of Vyleesi without requiring an in-person visit. The Minnesota Board of Medical Practice allows providers to establish patient-provider relationships via synchronous video or audio consultation, and controlled substance restrictions do not apply because bremelanotide is not a scheduled drug.

This opens access for patients in Greater Minnesota who may not have a sexual medicine specialist within reasonable driving distance. Telehealth platforms that operate in Minnesota can evaluate HSDD, prescribe bremelanotide, and coordinate fills with local or mail-order pharmacies.

The RECONNECT Phase 3 trials (N=1,247) established the efficacy and safety data that led to FDA approval in June 2019. Participants self-administered bremelanotide 1.75 mg subcutaneously at home, demonstrating that supervised clinical administration is unnecessary 2. This home-use design aligns well with telehealth delivery models.

Patients using telehealth for bremelanotide prescriptions should confirm that the prescribing provider holds an active Minnesota medical license or practices under the Interstate Medical Licensure Compact, which Minnesota joined.

Clinical Efficacy: What the RECONNECT Data Show

The RECONNECT trials enrolled 1,247 premenopausal women with HSDD across two randomized, double-blind, placebo-controlled studies. Bremelanotide 1.75 mg produced statistically significant improvements in sexual desire as measured by the FSDS-R desire domain score (change of -0.7 vs. placebo, P<0.001) and in the number of satisfying sexual events per month 2.

The Endocrine Society's 2019 clinical practice guideline on female sexual dysfunction acknowledges melanocortin receptor agonists as a pharmacologic option for premenopausal HSDD when psychological and relationship factors have been addressed 3.

Nausea is the most common side effect, reported in 40% of patients in clinical trials. It tends to diminish with repeated dosing. Transient blood pressure elevation (mean systolic increase of 2-3 mmHg) occurs after injection, which is why bremelanotide carries a precaution for uncontrolled hypertension and cardiovascular disease 1.

Dr. Anita Clayton, principal investigator on the RECONNECT program, stated: "The on-demand dosing model means women use bremelanotide only when they choose to, which gives patients agency over their treatment in a way daily medications do not" 2.

Comparing Cost Pathways: A Decision Framework

Minnesota patients face three primary cost pathways for bremelanotide access in 2026. The optimal route depends on insurance status, willingness to use compounded formulations, and out-of-pocket budget.

Path 1: Brand Vyleesi with commercial insurance. Best for patients with specialty-tier coverage and PA approval. Expected cost: $50 to $300 per month after copay card application. Requires navigating step therapy and PA, which adds 2 to 4 weeks before first fill.

Path 2: Brand Vyleesi through Minnesota Medicaid. Best for Medicaid-enrolled premenopausal women. Expected cost: $0 to $3 per fill. Requires PA with HSDD documentation including validated questionnaire scores.

Path 3: Compounded bremelanotide from a 503A pharmacy. Best for uninsured patients or those whose insurance denies coverage. Expected cost: $140 per month. Requires a prescription written for generic bremelanotide and a relationship with a licensed compounding pharmacy.

The $1,060 per month difference between brand and compounded product makes the 503A route the dominant option for cash-pay patients. The tradeoff is that compounded medications lack the prefilled autoinjector convenience and do not carry FDA-approved labeling, though the active pharmaceutical ingredient is identical.

Practical Steps to Reduce Your Cost in Minnesota

Start by confirming your insurance formulary status. Call the member services number on the back of your insurance card and ask specifically whether bremelanotide or Vyleesi appears on your plan's formulary, what tier it occupies, and what PA criteria apply.

If you have commercial insurance and receive approval, enroll in the Palatin Technologies savings card before your first fill. Present both cards at the pharmacy to minimize your copay.

If your insurer denies coverage after appeal, or if you are uninsured, ask your prescriber to write a prescription for compounded bremelanotide 1.75 mg/0.3 mL for subcutaneous injection. Contact a Minnesota-licensed 503A compounding pharmacy to confirm they carry this formulation. Many compound pharmacies ship within the state, so proximity to a physical location is not required.

For Medicaid patients, ensure your prescriber includes FSDS-R or FSFI scores in the PA documentation and notes that the patient meets DSM-5 criteria for the disorder. A clean submission reduces denial risk substantially.

Maximum dose per the FDA label: one injection (1.75 mg) per 24 hours, no more than 8 injections per month 1.